Amgen Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
Amgen (AMGN) reported strong third-quarter 2026 financial results, with total revenues reaching $10.4 billion, an 8% increase year-over-year. This growth was primarily driven by volume expansion across its product portfolio, including significant gains from Repatha, EVENITY, and TEZSPIRE. Non-GAAP EPS rose 14% to $6.45, reflecting robust top-line performance despite increased operating expenses related to R&D investments. Following strong execution through the first nine months of the year, Amgen raised its full-year 2026 revenue guidance to a range of $38.9 billion to $39.7 billion and increased its Non-GAAP EPS outlook to $22.90–$23.70. While some products like Prolia faced headwinds from biosimilar competition, the company's overall momentum in rare diseases and biosimilars remains strong.
Tickers: $AMGN
Topics: EPS Beat Guidance Raise Pharmaceutical Sales Revenue Growth